p27kip1 independently promotes neuronal differentiation and migration in the cerebral cortex

  1. Laurent Nguyen1,
  2. Arnaud Besson2,
  3. Julian Ik-Tsen Heng1,
  4. Carol Schuurmans3,
  5. Lydia Teboul1,5,
  6. Carlos Parras1,
  7. Anna Philpott4,
  8. James M. Roberts2, and
  9. François Guillemot1,6
  1. 1 Division of Molecular Neurobiology, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom;
  2. 2 Howard Hughes Medical Institute, Fred Hutchinson Cancer Research Center, Division of Basic Sciences, Seattle, Washington 98109, USA;
  3. 3 Department of Biochemistry and Molecular Biology, Institute of Maternal and Child Health, University of Calgary, Calgary, Alberta T2N 4N1, Canada;
  4. 4 Department of Oncology, Cambridge University, Hutchison/MRC Research Centre, Addenbrookes Hospital, Cambridge CB22XZ, United Kingdom

Abstract

The generation of neurons by progenitor cells involves the tight coordination of multiple cellular activities, including cell cycle exit, initiation of neuronal differentiation, and cell migration. The mechanisms that integrate these different events into a coherent developmental program are not well understood. Here we show that the cyclin-dependent kinase inhibitor p27Kip1 plays an important role in neurogenesis in the mouse cerebral cortex by promoting the differentiation and radial migration of cortical projection neurons. Importantly, these two functions of p27Kip1 involve distinct activities, which are independent of its role in cell cycle regulation. p27Kip1 promotes neuronal differentiation by stabilizing Neurogenin2 protein, an activity carried by the N-terminal half of the protein. p27Kip1 promotes neuronal migration by blocking RhoA signaling, an activity that resides in its C-terminal half. Thus, p27Kip1 plays a key role in cortical development, acting as a modular protein that independently regulates and couples multiple cellular pathways contributing to neurogenesis.

Keywords

Footnotes

  • 5

    5 Present address: Gene Targeting and Transgenic Unit, Mary Lyon Center, Medical Research Council, Harwell, Oxfordshire OX11 0RD, UK.

  • 6

    6 Corresponding author.

    6 E-MAIL Fguille{at}nimr.mrc.ac.uk; FAX 44-20-88162109.

  • Supplemental material is available at http://www.genesdev.org.

  • Article published online ahead of print. Article and publication date are online at http://www.genesdev.org/cgi/doi/10.1101/gad.377106

    • Received December 21, 2005.
    • Accepted April 6, 2006.
| Table of Contents

Life Science Alliance